Xenovaccinotherapy for colorectal cancer

Biomedicine and Pharmacotherapy

Volumn 61, Issue 2-3, 2007, Pages 125-130

  Seledtsov, Victor I ^a   Niza, Natalya A ^a   Felde, Mariya A ^a   Shishkov, Alexey A ^a   Samarin, Denis M ^a   Seledtsova, Galina V ^a   Seledtsov, Dmitriy V ^a  

^a INSTITUTE OF CLINICAL IMMUNOLOGY   (Russian Federation)

Author keywords

Colorectal cancer; Immunotherapy; Xenogenic polyantigenic vaccine

Indexed keywords

CANCER VACCINE; CYTOKINE; GAMMA INTERFERON; IMMUNOGLOBULIN G ANTIBODY; INTERLEUKIN 4; RECOMBINANT INTERLEUKIN 2; RONKOLEUKIN; TUMOR ANTIGEN; UNCLASSIFIED DRUG; XENOGENIC POLYANTIGENIC VACCINE;

ADULT; AGED; ANTIBODY TITER; ARTICLE; AUTOIMMUNE DISEASE; CANCER CELL; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DELAYED HYPERSENSITIVITY; DRUG EFFICACY; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLU LIKE SYNDROME; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOREACTIVITY; INJECTION SITE IRRITATION; LOW DRUG DOSE; MALE; MELANOMA CELL; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADULT; AGED; ANIMALS; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; CANCER VACCINES; CARCINOMA; COLORECTAL NEOPLASMS; DRUG SYNERGISM; FEMALE; HUMANS; IMMUNITY, CELLULAR; IMMUNOGLOBULIN G; INJECTIONS, SUBCUTANEOUS; INTERFERON TYPE II; INTERLEUKIN-2; INTERLEUKIN-4; MALE; MELANOMA; MICE; MIDDLE AGED; NEOPLASM STAGING; SURVIVAL ANALYSIS; TH1 CELLS; TH2 CELLS; VACCINATION;

EID: 34147120101     PISSN: 07533322     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopha.2006.09.016     Document Type: Article

References (18)

1. Habal N., Gupta R.K., Bilchik A.J., Yee R., Leopoldo Z., Ye W., et al. CancerVax, an allogeneic tumor cell vaccine, induces specific humoral and cellular immune responses in advanced colon cancer. Ann Surg Oncol 8 (2001) 389-401
2. Uyl-de Groot C.A., Vermorken J.B., Hanna Jr. M.G., Verboom P., Groot M.T., Bonsel G.J., et al. Immunotherapy with autologous tumor cell-BCG vaccine in patients with colon cancer: a prospective study of medical and economic benefits. Vaccine 23 (2005) 2379-2387
3. Tsuruma T., Hata F., Furuhata T., Ohmura T., Katsuramaki T., Yamaguchi K., et al. Peptide-based vaccination for colorectal cancer. Expert Opin Biol Ther 5 (2005) 799-807
4. Ward S., Casey D., Labarthe M.C., Whelan M., Dalgleish A., Pandha H., et al. Immunotherapeutic potential of whole tumor cells. Cancer Immunol Immunother 51 (2002) 351-357
5. Naftzger C., Takechi Y., Kohda H., Hara I., Vijayasaradhi S., and Houghton A.N. Immune response to a differentiation antigen induced by altered antigen: a study of tumor rejection and autoimmunity. Proc Natl Acad Sci U S A 93 (1996) 14809-14814
6. Steitz J., Bruck J., Steinbrink K., Enk A., Knop J., and Tuting T. Genetic immunization of mice with human tyrosinase-related protein 2: implications for the immunotherapy of melanoma. Int J Cancer 86 (2000) 89-94
7. Fong L., Brockstedt D., Benike C., Breen J.K., Strang G., Ruegg C.L., et al. Dendritic cell-based xenoantigen vaccination for prostate cancer immunotherapy. J Immunol 167 (2001) 7150-7156
8. Hawkins W.G., Gold J.S., Blachere N.E., Bowne W.B., Hoos A., Lewis J.J., et al. Xenogeneic DNA immunization in melanoma models for minimal residual disease. J Surg Res. 102 (2002) 137-143
9. Bergman P.J., McKnight J., Novosad A., Charney S., Farrelly J., Craft D., et al. Long-term survival of dogs with advanced malignant melanoma after DNA vaccination with xenogeneic human tyrosinase: a phase I trial. Clin Cancer Res. 9 (2003) 1284-1290
10. Seledtsov V.I., Shishkov A.A., Surovtseva M.A., Samarin D.M., Seledtsova G.V., Niza N.A., et al. Xenovaccinotherapy for melanoma. Eur J Dermatol 16 6 (2006)
11. Sebzda E., Mariathasan S., Ohteki T., Jones R., Bachmann M.F., and Ohashi P.S. Selection of the T cell repertoire. Annu Rev Immunol 17 (1999) 829-874
12. Dunn G.P., Bruce A.T., Ikeda H., Old L.J., and Schreiber R.D. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 3 (2002) 991-998
13. Khong H.T., and Restifo N.P. Natural selection of tumor variants in the generation of ''tumor escape'' phenotypes. Nat Immunol 3 (2002) 999-1005
14. Deriy L., Ogawa H., Gao G.-P., and Galili U. In vivo targeting of vaccinating tumor cells to antigen-presenting cells by a gene therapy method with adenovirus containing the α1,3-galactosyltransferase gene. Cancer Gene Therapy 12 (2005) 528-539
15. Galili U. Interaction of the natural anti-Gal antibody with α-galactosyl epitopes: a major obstacle for xenotransplantation in humans. Immunol Today 14 (1993) 480-482
16. Galili U., Rachmilewitz E.A., Peleg A., and Flechner I. A unique natural human IgG antibody with anti-α-galactosyl specificity. J Exp Med 160 (1984) 1519-1531
17. Rossi G.R., Unfer R.C., Seregina T., and Link C.J. Complete protection against melanoma in absence of autoimmune depigmentation after rejection of melanoma cells expressing alpha(1,3)galactosyl epitopes. Cancer Immunol Immunother 54 (2005) 999-1009
18. Clynes R., Takechi Y., Moroi Y., Houghton A., and Ravetch J.V. Fc receptors are required in passive and active immunity to melanoma. Proc Natl Acad Sci U S A 95 (1998) 652-656